Three years lat­er the FDA fi­nal­ly lifts its hold on Ap­tose drug, set­ting the stage for a re­turn to PhIb

Af­ter an al­most three-year halt im­posed by a clin­i­cal hold, Ap­tose Bio­sciences can fi­nal­ly re­sume the Phase Ib tri­al for its MYC in­hibitor.

The San Diego-based biotech $AP­TO ex­plained to­day that the clin­i­cal hold on the tri­al of AP­TO-253 was a con­se­quence of an event re­lat­ed to the in­fu­sion pro­ce­dure, which — a root cause in­ves­ti­ga­tion de­ter­mined — re­sult­ed from “chem­istry and man­u­fac­tur­ing based is­sues.” All of them have now been in­cor­po­rat­ed in an amend­ment to the IND ap­pli­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER